Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Amounts Included in Consolidated Statements of Operations) (Details)

v2.4.0.8
Discontinued Operations (Amounts Included in Consolidated Statements of Operations) (Details) (USD $)
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Net sales                 $ 1,130,630 $ 78,738 $ 597,729
Gross profit 383,000 325,000 90,000 0 7,000 0 60,000 12,000 797,815 78,738 597,729
Research and development                 23,710,183 16,890,482 15,154,365
Selling, general and administrative                 15,525,946 11,177,559 9,547,779
Total operating expenses 13,436,000 10,250,000 8,546,000 7,004,000 7,033,000 9,069,000 5,447,000 6,518,000 39,236,129 28,068,041 24,702,144
Other expense, net                 (4,261,144) (1,167,901) (943,161)
Income taxes                 0 0 7,880,143
Income from operations                 0 0 3,329,534
GDS Business and Cardiosonix Subsidiary [Member]
                     
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                      
Net sales                     7,684,689
Cost of goods sold                     2,324,427
Gross profit                     5,360,262
Research and development                     564,194
Selling, general and administrative                     308,220
Total operating expenses                     872,414
Other expense, net                     (1,084)
Income taxes                     1,157,230
Income from operations                     $ 3,329,534